Letter from the Editor

Dear Readers,

Welcome to this review of the 2017 ACR meeting, held in San Diego. This meeting is a great opportunity to catch up on the many developments occurring in Rheumatology over the past 12 months, with cutting edge talks from international leaders. However, many do not get the chance to attend this meeting – and others might have been there, but unable to attend all sessions of interest due to clashes in the programme, or simple exhaustion with the extensive schedule. Whether you are in one of these groups, or just want to revise what you learned in San Diego – this review is for you!

We have assembled reports from key areas discussed in the 2017 ACR meeting, to give you a broad view of what has been presented. There topics selected range from late breaking abstracts with data on the use of novel agents such as Sprifermin in degenerative joint disease, through discussing perhaps unexpected links between obesity and inflammation, to “State of the Art” talks on rheumatoid arthritis. Whatever your interests in rheumatology, I am sure that you will find something here that will stimulate you and hope that you will enjoy reading this excellent and helpful review.

With best wishes,

Robert Moots

 

Biography

Robert Moots is Professor of Rheumatology at the University of Liverpool. Qualifying in Medicine in London, he earned his PhD in immunology at the University of Oxford UK and worked at Harvard Medical School before returning to the UK to establish a new research group in Liverpool.

His research focuses on inflammatory diseases, from bench to bedside. He has published extensively, advises NICE, is Past Editor of Rheumatology and lectures all around the world. His group is EULAR Centre of Excellence. Clinical service remains important and his unit is a National Referral Centre.



Posted on 8 November 201715 March 2021